In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.
Rituximab is a chimeric anti-CD20 monoclonal antibody (mAb) used in B-cell malignancies, various autoimmune disorders and organ transplantation. Although administration of a single dose of rituximab results in full B-cell depletion in peripheral blood, there remains a residual B-cell population in s...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826303406516469760 |
|---|---|
| author | Kamburova, E Koenen, H Boon, L Hilbrands, L Joosten, I |
| author_facet | Kamburova, E Koenen, H Boon, L Hilbrands, L Joosten, I |
| author_sort | Kamburova, E |
| collection | OXFORD |
| description | Rituximab is a chimeric anti-CD20 monoclonal antibody (mAb) used in B-cell malignancies, various autoimmune disorders and organ transplantation. Although administration of a single dose of rituximab results in full B-cell depletion in peripheral blood, there remains a residual B-cell population in secondary lymphoid organs. These nondepleted B cells might be altered by exposure to rituximab with subsequent immunomodulatory effects. Therefore, we analyzed in vitro the effects of rituximab on proliferation, activation and differentiation of CD19(+) B cells by means of carboxyfluorescein succinimidyl ester (CFSE)-based multiparameter flow cytometry. Rituximab inhibited the proliferation of CD27(-) naïve, but not of CD27(+) memory B cells. Interestingly, upon stimulation with anti-CD40 mAb and interleukin-21 in the presence of rituximab there was an enrichment of B cells that underwent only one or two cell divisions and displayed an activated naïve phenotype (CD27(-)IgD(+)CD38(-/+)). The potency of prestimulated B cells to induce T-cell proliferation was increased by exposure of the B cells to rituximab. Of note, after stimulation with rituximab-treated B cells, proliferated T cells displayed a more Th2-like phenotype. Overall, these results demonstrate that rituximab can affect human B-cell phenotype and function, resulting in an altered outcome of B-T cell interaction. |
| first_indexed | 2024-03-07T06:02:12Z |
| format | Journal article |
| id | oxford-uuid:ec9a072b-ed3a-41c9-a36b-dbedf79ddf54 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:02:12Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:ec9a072b-ed3a-41c9-a36b-dbedf79ddf542022-03-27T11:18:36ZIn vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ec9a072b-ed3a-41c9-a36b-dbedf79ddf54EnglishSymplectic Elements at Oxford2012Kamburova, EKoenen, HBoon, LHilbrands, LJoosten, IRituximab is a chimeric anti-CD20 monoclonal antibody (mAb) used in B-cell malignancies, various autoimmune disorders and organ transplantation. Although administration of a single dose of rituximab results in full B-cell depletion in peripheral blood, there remains a residual B-cell population in secondary lymphoid organs. These nondepleted B cells might be altered by exposure to rituximab with subsequent immunomodulatory effects. Therefore, we analyzed in vitro the effects of rituximab on proliferation, activation and differentiation of CD19(+) B cells by means of carboxyfluorescein succinimidyl ester (CFSE)-based multiparameter flow cytometry. Rituximab inhibited the proliferation of CD27(-) naïve, but not of CD27(+) memory B cells. Interestingly, upon stimulation with anti-CD40 mAb and interleukin-21 in the presence of rituximab there was an enrichment of B cells that underwent only one or two cell divisions and displayed an activated naïve phenotype (CD27(-)IgD(+)CD38(-/+)). The potency of prestimulated B cells to induce T-cell proliferation was increased by exposure of the B cells to rituximab. Of note, after stimulation with rituximab-treated B cells, proliferated T cells displayed a more Th2-like phenotype. Overall, these results demonstrate that rituximab can affect human B-cell phenotype and function, resulting in an altered outcome of B-T cell interaction. |
| spellingShingle | Kamburova, E Koenen, H Boon, L Hilbrands, L Joosten, I In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| title | In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| title_full | In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| title_fullStr | In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| title_full_unstemmed | In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| title_short | In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| title_sort | in vitro effects of rituximab on the proliferation activation and differentiation of human b cells |
| work_keys_str_mv | AT kamburovae invitroeffectsofrituximabontheproliferationactivationanddifferentiationofhumanbcells AT koenenh invitroeffectsofrituximabontheproliferationactivationanddifferentiationofhumanbcells AT boonl invitroeffectsofrituximabontheproliferationactivationanddifferentiationofhumanbcells AT hilbrandsl invitroeffectsofrituximabontheproliferationactivationanddifferentiationofhumanbcells AT joosteni invitroeffectsofrituximabontheproliferationactivationanddifferentiationofhumanbcells |